title: Log reduction of multidrug-resistant Gram-negative bacteria by the neutrophil-derived recombinant bactericidal/permeability-increasing protein.
abstract: Multidrug-resistant (MDR) Gram-negative bacterial infections are a serious and ever-increasing threat for which limited therapeutic options exist. The bactericidal/permeability-increasing protein (BPI) is a cationic, neutrophil-derived, lipopolysaccharide (LPS)-binding protein that binds to Gram-negative bacteria (GNB) and LPS via its lipid A region. A recombinant fragment, rBPI-21, was studied extensively in clinical trials for meningococcal disease in the 1990s and exhibited no significant safety issues. In this report, a dose-dependent 1-2 log reduction of MDR Pseudomonas and Acinetobacter after 1h incubation with rBPI-21 using clinically achievable doses is described. Given the dearth of novel antimicrobials expected to emerge from the pharmaceutical pipeline in the near future, exploration of rBPI-21 to combat MDR GNB is now warranted.
authors.affiliation: Department of Medicine, Division of Infectious Diseases and Immunology, New York University School of Medicine, New York, NY 10016, USA.
authors.forename: Andrea
authors.initials: A
authors.lastname: Weitz
authors.forename: Russell
authors.initials: R
authors.lastname: Spotnitz
authors.forename: Jennifer
authors.initials: J
authors.lastname: Collins
authors.forename: Steven
authors.initials: S
authors.lastname: Ovadia
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Iovine
mesh_terms: D000150:Acinetobacter / Q000187:drug effects*; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology*; D001798:Blood Proteins / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D011549:Pseudomonas / Q000187:drug effects*; D011994:Recombinant Proteins / Q000235:genetics / Q000494:pharmacology
chemical_list: D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins; D011994:Recombinant Proteins; C021623:bactericidal permeability increasing protein
keywords: Bactericidal/permeability-increasing protein; Gram-negative bacteria; Innate immunity; Multidrug resistance; Novel antibiotic; rBPI-21